Hetero Healthcare and Enzene launched Perzea, India’s most affordable Pertuzumab biosimilar
Hyderabad (Telangana) [India], September 25: Hetero Healthcare Limited, in strategic collaboration with Enzene Biosciences, has launched Perzea, India’s most affordable Pertuzumab biosimilar. The introduction of this targeted therapy for HER2-positive breast cancer demonstrates the synergy between two healthcare leaders committed to advanced cancer treatment accessibility.
Innovation Meets Affordability
Pertuzumab plays a vital role in the standard of care for HER2-positive breast cancer worldwide. By leveraging Enzene’s patented EnzeneX™ technology, Perzea becomes not only affordable but also reliable in terms of quality and production efficiency. This innovation-driven partnership sets new standards for biologics in India.
Speaking on the occasion, Mr. M. Srinivas Reddy, Managing Director of Hetero Healthcare Limited, said:
“At Hetero Healthcare, we believe innovation must be purposeful. With Perzea, we integrate Enzene’s technology with our vision of affordability, ensuring patients in India can access advanced oncology medicines without compromise.”
Strengthening India’s Biopharma Ecosystem
The launch of Perzea highlights India’s growing capabilities in biologics manufacturing and biosimilar development. It also reinforces Hetero Healthcare’s dedication to delivering cutting-edge yet cost-effective therapies across oncology and other therapeutic areas.
About Hetero Healthcare
Hetero Healthcare Limited is recognised for its wide-ranging portfolio in oncology, critical care, and chronic disease management. The company continues to pioneer initiatives that make oncology medicines in India more accessible. Visit: www.heterohealthcare.com
About Enzene Biosciences
Enzene is a next-generation biologics manufacturer and the first to validate a fully connected continuous manufacturing (FCCM™) platform for commercial biologics supply. Its operations in Pune (India) and New Jersey (USA) focus on biologics innovation and affordability. Visit: www.enzene.com
Disclaimer: The article is for general information purposes only and should not be construed as professional medical advice. Always consult your doctor before taking any step.
